BristolMyers Squibb Company

Filed a patent for "compositions comprising antibodies that bind bcma and cd3 and methods of treatment" on Fri, August 18, 2023

Filed a patent for "co-crystals of nitroxyl donating compounds" on Wed, August 23, 2023

Filed a patent for "combination therapy using a ptpn11 inhibitor, a kras g12c inhibitor, and an egfr inhibitor" on Fri, August 11, 2023

Filed a patent for "methods of assessing citrullination and activity of pad4 modulators" on Fri, July 21, 2023

Filed a patent for "heterocyclic pad4 inhibitors" on Fri, July 21, 2023

Filed a patent for "biomarkers and methods of treatment of follicular lymphoma" on Tue, June 13, 2023

Filed a patent for "near real time sialic acid quantitation of glycoproteins" on Wed, June 14, 2023

Filed a patent for "cyclic peptide immunomodulators" on Wed, December 6, 2023

Filed a patent for "cell culture methods for producing therapeutic proteins" on Fri, February 2, 2024

Filed a patent for "combination therapy for lung cancer" on Wed, December 21, 2022

Filed a patent for "methods and systems for engineering cells and for target validation" on Fri, January 6, 2023

Filed a patent for "substituted benzimidazole compounds useful as inhibitors of tlr9" on Tue, January 31, 2023

Filed a patent for "milvexian pharmaceutical compositions" on Mon, February 6, 2023

Filed a patent for "assessment of bcma in biological samples" on Fri, February 10, 2023

Filed a patent for "isoindolinone glutarimide and phenyl glutarimide analogs as degraders of ret kinase" on Thu, February 16, 2023

Filed a patent for "urinary proteins levels associated with outcomes in heart failure with preserved ejection fraction and methods for predicting the risk of adverse outcomes in patients with heart failure with preserved ejection fraction, and associated methods of treatment" on Fri, February 17, 2023

Filed a patent for "use of myosin inhibitors for cytoprotection from hypoxic state" on Tue, February 28, 2023

Filed a patent for "methods of prognosis and treatment for heart failure with preserved ejection fraction using urinary protein levels" on Thu, March 2, 2023

Filed a patent for "pharmaceutical compositions for improving oral bioavailability" on Fri, March 17, 2023

Filed a patent for "tumor subtype assessment for cancer therapy" on Mon, March 20, 2023

Filed a patent for "pyrazolotriazinecarbonitriles useful as kinase inhibitors" on Mon, April 17, 2023

Filed a patent for "pyrrolidinone urea fpr2 agonists" on Tue, April 18, 2023

Filed a patent for "pyrrolidinone urea fpr2 agonists" on Tue, April 18, 2023

Filed a patent for "carbocyclic phenylpyrrolidinone urea fpr2 agonists" on Tue, April 18, 2023

Filed a patent for "cytotoxicity assay for assessing potency of therapeutic cell compositions" on Tue, April 18, 2023